Alyftrek, a next-generation triple-combination CFTR modulator, further improved the function of the defective CFTR protein in children ages 2 to 5 with cystic fibrosis (CF) who switched from Trikafta, new clinical trial data suggest. Vertex Pharmaceuticals, the company that markets both Alyftrek and Trikafta, presented the…